<DOC>
	<DOCNO>NCT00124397</DOCNO>
	<brief_summary>The aim study examine effect intensive cholesterol lower therapy tight blood pressure ( BP ) regulation endothelial function ( inner cell layer vessel determine dilatation ) type 2 diabetic patient without document cardiovascular ( CV ) disease . The hypothesis intensive cholesterol lower tight blood pressure regulation due good control group .</brief_summary>
	<brief_title>Atorvastatin Endothelial Function Type 2 Diabetes Mellitus ( ATTEND-Study )</brief_title>
	<detailed_description>Background : The prevalence diagnose type 2 diabetes mellitus ( DM ) estimate 2-4 % general population European country . DM associate increased frequency manifest atherosclerotic disease . Data prospective study demonstrate risk develop acute coronary syndrome ( ACS ) diabetic patient prior history coronary artery disease ( CAD ) equivalent risk observe non-diabetics ACS survivor . Most diabetic patient die CAD . Although DM primarily metabolic disorder , impose tremendous burden macro- micro-vessel disease.The important question primary prevention cardiovascular disease ( CVD ) DM remain unanswered . In major lipid-intervention study patient CAD include , subgroup DM least good effect lipid lower therapy statins non-diabetics . The recently publish Heart Protection Study support hypothesis favourable effect statins primary prevention CVD DM . The UK Prospective Diabetic Study prove tight blood pressure ( BP ) regulation reduces frequency micro- macrovascular endpoint . It suggest combined lipid lowering statin tight BP regulation additive effect DM patient . It well establish atherosclerotic process impact endothelial function.An improvement endothelial function cholesterol lower BP reduction may serve surrogate endpoint CAD . Objective : To assess effect intensive lipid lower endothelial function patient DM serum cholesterol level &lt; 6.5 mmol/l evaluate effect combine lipid lower tight BP regulation endothelial function patient group . Methods : This single-center , randomise , placebo-controlled study three treatment arm . Participants blindly allocate : 1. atorvastatin 80 mg daily 2. correspond placebo 3. open label treatment atorvastatin 80 mg daily tight BP regulation 5-10 mg amlodipine , 2-4 mg perindopril , 4-8 mg doxazosin mono- combination therapy aim BP &lt; 130/80 . Endothelial function evaluate baseline , 6 12 month non-invasively . A high resolution ultrasound scan perform right brachial artery ass post ischemic flow mediate change arterial diameter . Flow mediate dilatation ( FMD ) depend intact endothelium mediate via endogenous nitric oxid ( NO ) . To test non-endothelium dependent vasodilatation 0.4 mg sublingual nitroglycerin ( NG ) administrate . NG smooth muscle relaxant act source NO.There well describe relation tween endothelial function coronary artery brachial artery . Sample size : sample size study base follow assumption : 1 . High resolution ultrasound technique high accuracy reproducibility . 2 . The majority patient endothelial dysfunction 3 . As show previous clinical study , increase FMD 2 % significant 95 % confidence interval . 4 . Patients randomise atorvastatin one year treatment show improvement FMD leat 2 % compare placebo group . Patients treat openly atorvastatin BP regulation improvement FMD 2 % . Under assumption power 80 % 2 side alfa 5 % sample size 160 patient need .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Type 2 diabetes mellitus , Total cholesterol &lt; 6.5 mmol/l Signed informed consent Documented CAD peripheral vascular disease Treatment lipidlowering drug Contraindications HMGCoA reductase therapy Potential noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>